Phase I Study of Aprotinin in Advanced Breast Cancer
Sponsor: Dartmouth-Hitchcock Medical Center
Terminated
The FDA changed the labeling for this agent, and we felt we could not offer it to patients on a non-surgical study.
Other terminated trials from Dartmouth-Hitchcock Medical Center
- Anaplastic Astrocytoma · Aug 2025
- Lumbar Puncture · Phase NA · Dec 2023
- Vaccine Hesitancy · Phase NA · Jul 2023
- Pituitary Macroadenoma · Phase NA · Jul 2023
- Depression, Bipolar · Phase NA · Sep 2022
See all terminations from Dartmouth-Hitchcock Medical Center
Other Metastatic Breast Cancer trials with similar outcome
This PHASE1 trial investigates Metastatic Breast Cancer and is currently terminated or withdrawn. Dartmouth-Hitchcock Medical Center leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE1
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dartmouth-Hitchcock Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .